247 studies found for:    regeneron
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
Condition: Neovascular Age-Related Macular Degeneration
Interventions: Drug: REGN910-3;   Drug: Intravitreal Aflibercept Injection (IAI)
2 Completed
Has Results
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
Condition: Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions: Biological: VEGF Trap-Eye 2.0mg;   Drug: Sham
3 Active, not recruiting Study to Evaluate the Efficacy and Safety of REGN2222, for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
Condition: Respiratory Syncytial Virus Infections
Interventions: Drug: REGN2222;   Drug: Placebo
4 Enrolling by invitation A Study to Assess the Long-term Safety of Dupilumab (REGN668/SAR231893) Administered in Patients 6 to <18 Year of Age With Atopic Dermatitis (AD)
Condition: Atopic Dermatitis
Intervention: Drug: Dupilumab
5 Completed A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain
Condition: Sciatica
Interventions: Drug: REGN475;   Drug: Placebo Injection
6 Completed Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)
Condition: Atopic Dermatitis
Interventions: Drug: Dupilumab;   Drug: Midazolam;   Drug: Omeprazole;   Drug: Warfarin;   Drug: Caffeine;   Drug: Metoprolol
7 Completed Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Condition: Dermatitis, Atopic
Interventions: Drug: dupilumab;   Drug: placebo
8 Recruiting A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477
Condition: Healthy Volunteers
Interventions: Drug: REGN2477;   Drug: Placebo
9 Recruiting Study of Safety, Tolerability, and Pharmacokinetics of REGN3470-3471-3479 in Healthy Adult Volunteers
Condition: Healthy Volunteers
Interventions: Drug: REGN3470-3471-3479;   Drug: Placebo
10 Recruiting Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Condition: Advanced Cutaneous Squamous Cell Carcinoma
Intervention: Drug: REGN2810
11 Recruiting A Study to Assess the Efficacy and Safety of Dupilumab in Patients With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable
Condition: Atopic Dermatitis
Interventions: Drug: Dupilumab;   Drug: Placebo
12 Recruiting Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Subjects
Condition: Healthy
Intervention: Drug: REGN1033
13 Recruiting Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)
Condition: Nonproliferative Diabetic Retinopathy
Interventions: Drug: Intravitreal aflibercept injection [IAI];   Drug: Sham
14 Recruiting Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
Condition: Diabetic Macular Edema
Interventions: Drug: REGN910-3;   Drug: Intravitreal Aflibercept Injection (IAI)
15 Recruiting Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip
Condition: Osteoarthritis of the Knee or Hip
Interventions: Drug: Fasinumab;   Drug: Placebo
16 Recruiting Study of REGN2810 and REGN1979 in Patients With Lymphoma or Acute Lymphoblastic Leukemia
Conditions: Lymphoma;   Acute Lymphoblastic Leukemia
Interventions: Drug: REGN2810;   Drug: REGN1979
17 Recruiting A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain
Condition: Low Back Pain
Interventions: Drug: Fasinumab;   Drug: placebo
18 Recruiting Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
Conditions: Advanced Cancer;   Advanced Malignancies
Interventions: Drug: REGN2810;   Radiation: Hypofractionated radiotherapy;   Drug: Cyclophosphamide;   Drug: Docetaxel;   Drug: Carboplatin;   Drug: GM-CSF
19 Recruiting A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies
Conditions: Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia
Intervention: Drug: REGN1979 multiple dose levels
20 Recruiting Study of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
Condition: Homozygous Familial Hypercholesterolemia
Intervention: Drug: REGN1500

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years